Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you consider APBI in an otherwise-suitable patient who has ITC in a sentinel lymph node?
Answer from: Radiation Oncologist at Community Practice
I would treat ITC like node negative and would treat with APBI if otherwise suitable.
Sign in or Register to read more
3694
Related Questions
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
What are your top takeaways in Breast Cancer from ASCO 2025?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
What are your top takeaways in Medical Oncology from SABCS 2024?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
For patients between 40-49 years old who undergo lumpectomy, how do you choose between offering PBI per the updated PBI guidelines or boosting based on boost guidelines?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Would you recommend PMRT to a clinically node positive (biopsy proven axillary node and indeterminate single IMN node) BRCA positive patient with multiple medical co-morbidities including scleroderma and ILD who is treated with neoadjuvant chemotherapy (NAC) and mastectomy who converts to ypT0/ypN0?